The global therapeutic nuclear medicines market size accounted for USD 1,380 million in 2024 and is expected to exceed around USD 2,080 million by 2034, growing at a CAGR of 4.2% from 2024 to 2034.
The Therapeutic Nuclear Medicines Market deals with the development, distribution and application of radiopharmaceuticals for treatments. Medicine also known as radionuclide therapy or molecular radiotherapy are medicines which use radioactive substances to cure diseases. These medicines are mostly used for treating cancer, thyroid and some of the cardiovascular and neurological diseases. The rise in global cancer prevalence is the major growth factor which increases the demand for these medications. This is leading towards the adoption of cancer services for the patients in the developing areas.
The Therapeutic Nuclear Medicines Market is anticipated to grow significantly due to the technological advancements in radiopharmaceuticals that focus on expanding their target range of these medicines in various conditions. Additionally, the rising demand is also increasing the partnerships between the companies and medicine providers which is leading towards the expansion of the supply chain. The rising focus on R&D by Russian organizations is anticipated to bring growth opportunities in the European region. The rising prevalence of chronic illness in Germany and the growing Italian geriatric population will also contribute significantly in the upcoming years.
Published by Ajit Bansod
